| [1] | President's Council on Bioethics (2003) Beyond therapy: Biotechnology and the pursuit of happiness. New York: Dana Press. 400 p.
|
| [2] | McKibben W (2003) Enough: Staying human in an engineered age. New York: Times Books. 271 p.
|
| [3] | Callahan D (2003) What price better health? Hazards of the research imperative. Berkeley: University of California Press. 329 p.
|
| [4] | Elliott C (2003) Better than well: American medicine meets the American dream. New York: W. W. Norton. 357 p.
|
| [5] | Fukuyama F (2003) Our posthuman future: Consequences of the biotechnology revolution. New York: Picador. 272 p.
|
| [6] | Rothman S, Rothman D (2003) The pursuit of perfection: The promise and perils of medical enhancement. New York: Pantheon Books. 292 p.
|
| [7] | Kass LR (2002) Life, liberty, and the defense of dignity: The challenge for bioethics. San Francisco: Encounter Books. 313 p.
|
| [8] | Kristol W, Cohen E (2002) The future is now: America confronts the new genetics. Lanham (Maryland): Rowman and Littlefield. 357 p. editors.
|
| [9] | Sandel S2004 The case against perfection. Atlantic Monthly April51–62.
|
| [10] | Isaacson W (2003) Benjamin Franklin: An American life. New York: Simon and Schuster. 590 p.
|
| [11] | Whorton J (1984) Crusaders for fitness: The history of American health reformers. Princeton (New Jersey): Princeton University Press. 359 p.
|
| [12] | Caplan AL (2004) Is biomedical research too dangerous to pursue? Science 303: 1142.
|
| [13] | Saint Teresa of Avila (1964) The way of perfection. Garden City, New York: Image Books. 320 p. In Peers EA, translator. Available: www.ccel.org/t/teresa/way/main.html. Accessed 16 October 2004.
|
| [14] | Pinker S (2002) The blank slate: The modern denial of human nature. New York: Viking. 509 p.
|
| [15] | Tenner E (2003) Our own devices: The past and future of body technology. New York: Alfred A. Knopf. 314 p.
|
| [16] | Moynihan R (2002) Drug firms hype disease as sales ploy, industry chief claims. BMJ 324: 867.
|
| [17] | Mundy A (2001) Dispensing with the truth: The victims, the drug companies, and the dramatic story behind the battle over Fen-Phen. New York: St. Martin's Press. 402 p.
|
| [18] | Barrett A2004 Wyeth: The class action that wouldn't quit. Business Week 52488.
|
| [19] | Writing Group for the Women's Health Initiative Investigators (2002) Risks and benefits of estrogen plus progestin in healthy postmenopausal women: Principal results from the Women's Health Initiative randomized controlled trial. JAMA 288: 321–333.
|
| [20] | Whittington C, Kendall T, Fonagy P, Cottrell D, Cotgrove A, et al. (2004) Selective serotonin reuptake inhibitors in childhood depression: Systematic review of published versus unpublished data. Lancet 363: 1341–1344.
|
| [21] | Kassirer J (2004) On the take: How medicine's complicity with big business can endanger your health. New York: Oxford University Press. 251 p.
|
| [22] | Moynihan R, Heath I, Henry D (2002) Selling sickness: The pharmaceutical industry and disease mongering. BMJ 324: 886–891.
|
| [23] | Greider K (2003) The big fix: How the pharmaceutical industry rips off American consumers. New York: Public Affairs. 189 p.
|
| [24] | Angell M (2004) The truth about the drug companies: How they deceive us and what to do about it. New York: Random House. 305 p.
|
| [25] | Elliott C (2004) Pharma buys a conscience. Am Prospect 12(17): 16–20.
|
